Abstract
The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of persons aged 11-12 years to protect against certain diseases, including human papillomavirus (HPV)-associated cancers, meningococcal disease, and pertussis (1). A booster dose of quadrivalent meningococcal conjugate vaccine (MenACWY) is recommended at age 16 years, and serogroup B meningococcal vaccine (MenB) may be administered to persons aged 16-23 years (1). To estimate vaccination coverage among adolescents in the United States, CDC analyzed data from the 2018 National Immunization Survey-Teen (NIS-Teen) which included 18,700 adolescents aged 13-17 years.* During 2017-2018, coverage with ≥1 dose of HPV vaccine increased from 65.5% to 68.1%, and the percentage of adolescents up-to-date† with the HPV vaccine series increased from 48.6% to 51.1%, although the increases were only observed among males. Vaccination coverage increases were also observed for ≥1 MenACWY dose (from 85.1% to 86.6%) and ≥2 MenACWY doses (from 44.3% to 50.8%). Coverage with tetanus and reduced diphtheria toxoids and acellular pertussis vaccine (Tdap) remained stable at 89%. Disparities in coverage by metropolitan statistical area (MSA)§ and health insurance status identified in previous years persisted (2). Coverage with ≥1 dose of HPV vaccine was higher among adolescents whose parents reported receiving a provider recommendation; however, prevalence of parents reporting receiving a recommendation for adolescent HPV vaccination varied by state (range=60%-91%). Supporting providers to give strong recommendations and effectively address parental concerns remains a priority, especially in states and rural areas where provider recommendations were less commonly reported.
Highlights
Vaccines are recommended for adolescents to prevent diphtheria, pertussis, tetanus, meningococcal disease, and cancers caused by human papillomavirus (HPV)
Adolescents whose parents reported having received a provider recommendation were more likely to have received HPV vaccination compared with adolescents whose parents did not report a provider recommendation
human papillomavirus (HPV) vaccination has resulted in large declines in the prevalence of vaccine type HPV infections among adolescent girls and young adults [9], as well as decreases in cervical precancers [10], continuing to improve HPV vaccination coverage for all adolescents, male and female, will ensure they are protected from HPV infection and diseases caused by HPV, including cancers
Summary
Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2018. NIS-Teen is an annual survey that monitors vaccines received by adolescents aged 13–17 years in the 50 states, the District of Columbia, selected local areas, and U.S territories.¶ NISTeen is conducted among parents and guardians of eligible adolescents identified using a random-digit–dialed sample of cell phone numbers.** During the telephone interview, information is obtained on the sociodemographic characteristics of the teen and household, and contact information and consent to contact the teen’s vaccination providers are requested. A description of NIS-Teen single-frame survey methodology and its effect on reported vaccination estimates is available at https://www.cdc.gov/vaccines/imz-managers/coverage/teenvaxview/pubspresentations/dual-to-single-frame-teen.html. The landline telephone–sample frame that was used from 2006 through 2017 was dropped because of the declining number of landline-only households in the United States SAS-callable SUDAAN (version 11; SAS Institute) was used to conduct all analyses
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
